BMJ. 1999 Jan 16; 318(7177): 193.
PMCID: PMC1114674
John Barthelow Classen
Editor—Jefferson’s editorial about vaccination and its adverse effects mentions our research.1 We found that immunisation starting at birth was associated with a decreased risk of insulin dependent diabetes, while immunisation starting after age 2 months was associated with an increased risk of diabetes in both rodents and humans.2 We initiated a collaboration with Dr Jaakko Tuomilehto to study the effect of Haemophilus influenzae type b vaccine on the incidence of diabetes. Roughly 116 000 Finnish children were randomised to receive either four doses of the vaccine, starting at 3 months of age, or one dose at 24 months of age.3We calculated the incidence of insulin dependent diabetes in both groups until age 10 and in a group that did not receive the vaccine—a cohort that included all 128 500 children born in Finland in the 24 months before the study of the vaccine began.
A conference was held in Bethesda, Maryland, in May 1998 to discuss our data. At the conference we stated that the data on the vaccine support our published findings that immunisation starting after the age of 2 months is associated with an increased risk of diabetes. Our analysis is further supported by a similar rise in diabetes after immunisation with H influenzae type b vaccine in the United States4 and United Kingdom.5Furthermore, the increased risk of diabetes in the vaccinated group exceeds the expected decreased risk of complications of H influenzae meningitis.
Research into immunisation has been based on the theory that the benefits of immunisation far outweigh the risks from delayed adverse events and so long term safety studies do not need to be performed. When looking at diabetes—only one potential chronic adverse event—we found that the rise in the prevalence of diabetes may more than offset the expected decline in long term complications of H influenzae meningitis. Thus diabetes induced by vaccine should not be considered a rare potential adverse event. The incidence of many other chronic immunological diseases, including asthma, allergies, and immune mediated cancers, has risen rapidly and may also be linked to immunisation.
We believe that the public should be fully informed that vaccines, though effective in preventing infections, may have long term adverse effects. An educated public will probably increasingly demand proper safety studies before widespread immunisation. We believe that the outcome of this decision will be the development of safer vaccine technology.